Journal: Methods in Molecular Biology

Article Title: Antigen Processing

doi: 10.1007/978-1-62703-218-6

Figure Lengend Snippet: Fig. 2. Separation of DC from the spleen of mice treated with Flt3L in vivo into discrete subpopulations. pDC and cDC can be identi fi ed on the basis of differential expression of CD317 and CD11c and the cDC readily separated into CD8 + and CD8 − subpopulations using the same markers as used for untreated mice, regardless of whether the Flt3L was ( a ) admin- istered via a Flt3L secreting melanoma or ( b ) administered directly via subcutaneous injection. In both cases both popula- tions are expanded but the CD8 + fraction is expanded to a much greater extent.

Article Snippet: Puri fi ed recombinant human or murine Flt3L is commercially available, e.g. from R&D Systems (human; Cat.: 308-FK) or eBiosciences (murine; Cat.:14-8001-62).

Techniques: In Vivo, Quantitative Proteomics, Injection

Journal: Methods in Molecular Biology

Article Title: Antigen Processing

doi: 10.1007/978-1-62703-218-6

Figure Lengend Snippet: Fig. 3. Separation of DC generated in Flt3L bone marrow cultures into discrete subpopulations. pDC can be separated from cDC using a combination of CD11c and CD317. Although cDC generated in these cultures do not express CD4 or CD8 they are still separated into CD8 + and CD8 − equivalents using a combination of other markers, most commonly CD24 and CD11b or CD172a.

Article Snippet: Puri fi ed recombinant human or murine Flt3L is commercially available, e.g. from R&D Systems (human; Cat.: 308-FK) or eBiosciences (murine; Cat.:14-8001-62).

Techniques: Generated

Journal: Methods in Molecular Biology

Article Title: Antigen Processing

doi: 10.1007/978-1-62703-218-6

Figure Lengend Snippet: Fig. 4. Modi fi cation of cDC subpopulations in Flt3L bone marrow cultures. Addition of GM-CSF or IL-3 on day 6 of culture produces an increase in the proportion of CD103 + DC.

Article Snippet: Puri fi ed recombinant human or murine Flt3L is commercially available, e.g. from R&D Systems (human; Cat.: 308-FK) or eBiosciences (murine; Cat.:14-8001-62).

Techniques:

Journal: Methods in Molecular Biology

Article Title: Antigen Processing

doi: 10.1007/978-1-62703-218-6

Figure Lengend Snippet: Fig. 1. Generation of steady-state DC equivalents in vitro. Typical FACS pro fi le showing gating allowing for DC subset sorting from an Flt3L culture on day 7.

Article Snippet: Puri fi ed recombinant human or murine Flt3L is commercially available, e.g. from R&D Systems (human; Cat.: 308-FK) or eBiosciences (murine; Cat.:14-8001-62).

Techniques: In Vitro

Journal: Leukemia

Article Title: Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.

doi: 10.1038/sj.leu.2402558

Figure Lengend Snippet: Figure 3 (a) Dephosphorylation of TDFLT3 by HA. TDFLT3/32D and WtFLT3/32D (with 50 ng/ml FL) were treated with HA at 0.1, 0.3 and 1.0 M for 12 h. Cell lysates were immunoprecipitated by anti- FLT3 antibody and immunoblotted by anti-phosphotyrosine antibody or by anti-FLT3 antibody. Whole cell lysates were also immunoblotted by anti-FLT3 antibody and anti-Actin antibody for loading control. (b) Dephosphorylation of MAPK, Akt and STAT5a in MtFLT3/32D treated with HA. Cells were cultured with or without 0.3 MHA and lysed after 12 h. Whole cell lysates were immunoblotted by anti- MAPK and phospho-MAPK antibodies. Cell lysates were immunoprec- ipitated by anti-Akt or by anti-STAT5a antibodies, and immunoblotted by indicated antibodies.

Article Snippet: Recombinant human FLT3 ligand (FL) was purchased from R&D Systems (Minneapolis,

Techniques: De-Phosphorylation Assay, Immunoprecipitation, Control, Cell Culture

Journal: Leukemia

Article Title: Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.

doi: 10.1038/sj.leu.2402558

Figure Lengend Snippet: Figure 4 Association of FLT3 with Hsp90. WtFLT3/32D stimulated with or without 50 ng/ml FL for 10 min were analyzed by immunopre- cipitation followed by immunoblotting using indicated antibodies. TDFLT3/32D was treated with HA at 0.03, 0.1 and 0.3 M HA for 12 h and was assayed. For detection of Hsp90 expression levels, whole cell lysates were immunoblotted by anti-Hsp90 antibody.

Article Snippet: Recombinant human FLT3 ligand (FL) was purchased from R&D Systems (Minneapolis,

Techniques: Western Blot, Expressing